Secukinumab Provides Greater 52-Week Sustained Relief in Dermatology-Specific Quality-of-Life Impact Than Ustekinumab
Document Type
Abstract
Publication Date
June 2017
Journal Title
Journal of the American Academy of Dermatology
Department
Dermatology
Recommended Citation
Gottlieb, A., Pariser, D., Tsai, T., Pinter, A., Zhao, Y., Gilloteau, I., Davenport, E., Guana, A., & Reich, K. (2017). Secukinumab Provides Greater 52-Week Sustained Relief in Dermatology-Specific Quality-of-Life Impact Than Ustekinumab. Journal of the American Academy of Dermatology, 76 (6 Suppl. 1), AB230. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/47
COinS
